Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group.
Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R. Newling DW, et al. Among authors: sylvester r. Eur Urol. 1995;27(2):110-6. doi: 10.1159/000475139. Eur Urol. 1995. PMID: 7744151 Clinical Trial.
Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).
Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R. Newling DW, et al. Among authors: sylvester r. J Urol. 1993 Dec;150(6):1840-4. doi: 10.1016/s0022-5347(17)35911-6. J Urol. 1993. PMID: 8230517 Clinical Trial.
The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. Robinson MR, et al. Among authors: sylvester r. Eur Urol. 1995;28(4):273-83. Eur Urol. 1995. PMID: 8575493 Clinical Trial.
Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
Kurth K, Tunn U, Ay R, Schröder FH, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M, Sylvester R. Kurth K, et al. Among authors: sylvester r. J Urol. 1997 Aug;158(2):378-84. doi: 10.1016/s0022-5347(01)64484-7. J Urol. 1997. PMID: 9224307 Clinical Trial.
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
de Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R. de Voogt HJ, et al. Among authors: sylvester r. Eur Urol. 1998;33(2):152-8. doi: 10.1159/000019547. Eur Urol. 1998. PMID: 9519356 Clinical Trial.
500 results